3rd Quarter - Report — PHARMACEUTICAL CARE MANAGEMENT ASSOCIAT… for PHARMACEUTICAL CARE MANAGEMENT ASSOCIAT… (2009)

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm

PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION

Client

PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION

Income

—

Expenses

$325,548

Expense method

C: businesses, Internal Revenue Code section 162(e)

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing	Filed	Amount	Counted
3rd Quarter - Report (this page)	Oct 19, 2009	$325,548	Replaced
3rd Quarter - Amendment	Oct 20, 2009	$361,857	Yes

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Establishing a regulatory approval pathway for biogeneric drugs - HR 1427 / S 726 Promoting Innovation and Access to Life Saving Medicine Act and HR 1548 Pathway for Biosimilars Act Items related to the application of drug benefits to public plans and health exchange, including PBM disclosure, in HR 3200, S 1679 America's Health Future Act.

Lobbyist	Covered position, as disclosed
JONATHAN M HEAFITZ	—
GREG SCOTT JOHNSON	—
MARK D MERRITT	—

Contacted: Federal Trade Commission (FTC); Medicare Payment Advisory Commission (MedPAC); Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); SENATE

Bills named: H.R. 1427 (111th), H.R. 3200 (111th), H.R. 1548 (111th)

Medicare/Medicaid MMM

Issues related to Medicare/Medicaid drug coverage including pharmacy payments, reimbursements, competition and plan administration, electronic prescribing, chronic care, PBM disclosure. Health reform proposals impacting prescription drug coverage - including formulary requirements, generic drug copayments, direct negotiation, Medicaid rebate changes, applying Medicaid rebates in Medicare. HR 3200, S 1679 America's Health Future Act

Lobbyist	Covered position, as disclosed
JONATHAN M HEAFITZ	—
GREG SCOTT JOHNSON	—
MARK D MERRITT	—

Contacted: Medicare Payment Advisory Commission (MedPAC); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); Executive Office of the President (EOP); SENATE; Federal Trade Commission (FTC)

Bills named: H.R. 3200 (111th)

Pharmacy PHA

Items related to the application of drug benefits to public plans and health exchange, including PBM disclosure, in HR 3200, S 1679 Americas Health Future Act

Lobbyist	Covered position, as disclosed
JONATHAN M HEAFITZ	—
GREG SCOTT JOHNSON	—
MARK D MERRITT	—

Contacted: Medicare Payment Advisory Commission (MedPAC); Federal Trade Commission (FTC); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); Executive Office of the President (EOP); SENATE

Bills named: H.R. 3200 (111th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.